Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DCTH vs CVM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: DCTH 5 – 1 CVM Matrix Metrics: DCTH 6 – 4 CVM

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 0.0% operating margin) and revenue trajectory (+70.7% vs. -62.7% YoY).
  • Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCTH vs CVM
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66

6-Pillar Scorecard Institutional Category Breakdown (DCTH 5 – 1 CVM)

Columns: Metric · DCTH · CVM
1. Valuation Multiples CVM
Forward P/E N/M 23.0x
Trailing P/E 133.6x 23.0x
PEG Ratio 1.60x 1.12x
EV / Revenue 6.3x N/M
2. Growth & Scale DCTH
Revenue Growth (YoY) +70.7% -62.7%
Earnings Growth (YoY) +750.0% +0.0%
TTM Revenue (USD) $110M $28,558
Market Cap $743.8M $20.9M
3. Profitability & Quality DCTH
Gross Margin 87.6% N/A
Operating Margin 5.2% 0.0%
Net Profit Margin 6.0% 0.0%
Return on Equity (ROE) 5.4% -252.5%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $20M -$17M
Cash Flow Margin 18.3% N/A
Net Cash / Leverage $53M Net Cash $6.6M Net Debt (1.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 109.3% (43rd %ile) N/A (N/A)
Put/Call OI Skew 0.11x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 82.4% of Rev ($91M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCTH (6) vs CVM (4)
Institutional Metric DCTH CVM Criterion Row Edge
Market Capitalization
Scale
$743.8M $20.9M Larger Scale DCTH
Trailing P/E Ratio
Valuation
133.6x 23.0x Lower Multiple CVM
Forward P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY)
Growth
+70.7% -62.7% Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.2% 0.0% Higher Margin DCTH
Net Profit Margin
Profitability
6.0% 0.0% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
5.4% -252.5% Higher ROE DCTH
52-Week Range Position
Momentum
80% ($8–$23) 10% ($1–$8) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.63β · 131% Vol 0.65β · 120% Vol Lower Realized Risk CVM
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 56.6 / 100 (HOLD) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$110M $28,558 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.60x PEG · 6.3x EV/Rev 1.12x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($53M Net Cash) -$17M ($6.6M Net Debt (1.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +50.94 pp
DCTH: +39.77% · CVM: -11.17%
3M Horizon DCTH +16.73 pp
DCTH: +16.73% · CVM: +0.0%
6M Horizon DCTH +85.02 pp
DCTH: +77.46% · CVM: -7.56%
1Y Horizon DCTH +196.36 pp
DCTH: +120.38% · CVM: -75.98%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DCTH Revenue CVM Revenue DCTH Op. Margin CVM Op. Margin Margin Leader
FY2013 $0M $0M -4179.6% -12450.1% DCTH
FY2014 $0M $0M -1805.8% -9721.4% DCTH
FY2015 $0M N/A -870.6% N/A DCTH
FY2021 $0M N/A -690.0% N/A DCTH
FY2022 $0M N/A -1245.1% N/A DCTH
FY2023 $0M N/A -1849.0% N/A DCTH
FY2024 $40M N/A -33.4% N/A DCTH
FY2025 $90M N/A 0.8% N/A DCTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DCTH vs CVM Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 0.0% operating margin) and revenue trajectory (+70.7% vs. -62.7% YoY). Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), DCTH cumulative revenue shifted +125.0% while CVM shifted N/A. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.

CVM screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus CVM (-252.5% ROE) capital efficiency.

In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.